Pfizer Rx-To-OTC Comments: Study Before You Switch

FDA should evaluate whether nonprescription Claritin has increased access and lowered costs for allergy sufferers before deciding whether to force the OTC switch of other second-generation antihistamines, Pfizer asserts in May 7 comments to the agency